一分钟看懂
这是一项关于多发性骨髓瘤的III 期研究，登记的药物或干预包括Cevostamab；Pomalidomide；Dexamethasone；Daratumumab；Elotuzumab；Carfilzomib，当前状态为招募中。登记地点显示中国广州、南京、青岛、昆明等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Cevostamab；Pomalidomide；Dexamethasone；Daratumumab；Elotuzumab；Carfilzomib · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun yat-sen University Cancer Center · 广州
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School · 南京
- The Affiliated Hospital Of Qingdao University · 青岛
- The First Affilliated Hospital of Kunming Medical University · 昆明
- The First Affiliated Hospital, Zhejiang University School of Medicine - Qingchun Campus - PPDS · 杭州
- Nanfang Hospital, Southern Medical University · 广州
- Qilu Hospital of Shandong University · 济南
- The First Affiliate Hospital of Guangxi Medical University · 南宁
- Zhongshan Hospital Fudan University · 上海
- Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine · 上海
- The First Affiliated Hospital of Soochow University · 苏州
- The First Affiliated Hospital of Wenzhou Medical University · 温州
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology · 武汉
公开的入选条件
- * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to start of administration of study treatment.
- * Individuals with ECOG Performance Status of 2 solely due to local symptoms of myeloma (e.g., pain) are eligible
- * MM diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
- * Received one to three lines of prior therapy that included at least two consecutive cycles of either of the following: A regimen containing an anti-CD38 therapy, a regimen containing lenalidomide
- * Participants must have measurable disease during screening
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07555938；登记信息更新于 2026-09-11。